AU2013295924B2 - Crystal form of cabazitaxel and preparation method thereof - Google Patents

Crystal form of cabazitaxel and preparation method thereof Download PDF

Info

Publication number
AU2013295924B2
AU2013295924B2 AU2013295924A AU2013295924A AU2013295924B2 AU 2013295924 B2 AU2013295924 B2 AU 2013295924B2 AU 2013295924 A AU2013295924 A AU 2013295924A AU 2013295924 A AU2013295924 A AU 2013295924A AU 2013295924 B2 AU2013295924 B2 AU 2013295924B2
Authority
AU
Australia
Prior art keywords
cabazitaxel
crystalline form
carbon atoms
hydrate
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013295924A
Other languages
English (en)
Other versions
AU2013295924A1 (en
Inventor
Jing Li
Quanxing Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing Sintaho Pharmaceutical Co Ltd
Original Assignee
Chongqing Sintaho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Sintaho Pharmaceutical Co Ltd filed Critical Chongqing Sintaho Pharmaceutical Co Ltd
Publication of AU2013295924A1 publication Critical patent/AU2013295924A1/en
Priority to AU2016200343A priority Critical patent/AU2016200343B2/en
Application granted granted Critical
Publication of AU2013295924B2 publication Critical patent/AU2013295924B2/en
Assigned to CHONGQING SINTAHO PHARMACEUTICAL CO., LTD. reassignment CHONGQING SINTAHO PHARMACEUTICAL CO., LTD. Request for Assignment Assignors: Chongqing Taihao Pharmaceutical Co., Ltd.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
AU2013295924A 2012-07-25 2013-07-18 Crystal form of cabazitaxel and preparation method thereof Active AU2013295924B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016200343A AU2016200343B2 (en) 2012-07-25 2016-01-21 Crystal form of cabazitaxel and preparation method thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210259595.3 2012-07-25
CN201210259595.3A CN102746258B (zh) 2012-07-25 2012-07-25 卡巴他赛的结晶形式及其制备方法
PCT/CN2013/079575 WO2014015760A1 (zh) 2012-07-25 2013-07-18 卡巴他赛的结晶形式及其制备方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016200343A Division AU2016200343B2 (en) 2012-07-25 2016-01-21 Crystal form of cabazitaxel and preparation method thereof

Publications (2)

Publication Number Publication Date
AU2013295924A1 AU2013295924A1 (en) 2014-10-23
AU2013295924B2 true AU2013295924B2 (en) 2016-02-18

Family

ID=47026807

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013295924A Active AU2013295924B2 (en) 2012-07-25 2013-07-18 Crystal form of cabazitaxel and preparation method thereof
AU2016200343A Active AU2016200343B2 (en) 2012-07-25 2016-01-21 Crystal form of cabazitaxel and preparation method thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016200343A Active AU2016200343B2 (en) 2012-07-25 2016-01-21 Crystal form of cabazitaxel and preparation method thereof

Country Status (8)

Country Link
US (1) US9353076B2 (enExample)
EP (2) EP2835369B1 (enExample)
JP (1) JP6329135B2 (enExample)
CN (1) CN102746258B (enExample)
AU (2) AU2013295924B2 (enExample)
CA (2) CA2870569A1 (enExample)
IN (1) IN2014MN01962A (enExample)
WO (1) WO2014015760A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2688877B1 (en) 2011-04-12 2017-03-08 Teva Pharmaceuticals International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN104220431A (zh) * 2012-03-08 2014-12-17 伊瓦克斯国际有限责任公司 卡巴他赛的固态形式及其制备方法
CN102746258B (zh) * 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103819428B (zh) * 2012-11-19 2016-01-13 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇的溶剂化物的晶型及其制备方法
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
KR101429543B1 (ko) 2012-12-13 2014-08-14 주식회사 삼양바이오팜 카바지탁셀의 신규 결정형 및 그 제조방법
CN103044364B (zh) * 2013-01-07 2016-01-20 重庆泰濠制药有限公司 一种卡巴他赛无定形晶及其制备方法
WO2014128728A2 (en) * 2013-02-25 2014-08-28 Laurus Labs Private Limited Solid forms of cabazitaxel and processes for preparation thereof
CN103450119B (zh) * 2013-09-24 2015-06-17 天津炜捷制药有限公司 一种卡巴他赛晶型w及其制备方法
EP2865674A1 (en) * 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
CN105461664A (zh) * 2014-08-21 2016-04-06 中国医学科学院药物研究所 卡巴他赛晶n5型物质及制备方法和其组合物与用途
CN105461665A (zh) * 2014-08-21 2016-04-06 中国医学科学院药物研究所 卡巴他赛晶n6型物质及制备方法和其组合物与用途
CA3010514A1 (en) 2016-01-15 2017-07-20 Zhuhai Beihai Biotech Co., Ltd. Compositions and formulations including cabazitaxel and human serum albumin
EP3509569A1 (en) * 2016-09-07 2019-07-17 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
CN112055588B (zh) 2018-04-20 2023-09-08 珠海贝海生物技术有限公司 卡巴他赛的制剂和组合物
CN113429369B (zh) * 2021-07-23 2022-12-02 无锡紫杉药业有限公司 一种高效的卡巴他赛纯化方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060815A (zh) * 2010-12-24 2011-05-18 重庆泰濠制药有限公司 一种紫杉烷类化合物的制备方法
CN102503913A (zh) * 2011-10-20 2012-06-20 江苏红豆杉生物科技有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
WO2013034979A2 (en) * 2011-09-09 2013-03-14 Scinopharm Taiwan, Ltd. Crystalline forms of cabazitaxel
WO2013080217A2 (en) * 2011-11-28 2013-06-06 Fresenius Kabi Oncology Ltd. Crystalline forms of carbazitaxel and process for preparation thereof
WO2013088335A1 (en) * 2011-12-13 2013-06-20 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9742002A3 (en) 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
CN101525321B (zh) * 2008-03-06 2012-03-07 上海希迪制药有限公司 多烯紫杉醇倍半水结晶体及其制备方法
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
EP2688877B1 (en) * 2011-04-12 2017-03-08 Teva Pharmaceuticals International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN102336726B (zh) * 2011-09-30 2014-11-26 重庆泰濠制药有限公司 一种卡巴他赛的制备方法
US9772339B2 (en) * 2011-09-30 2017-09-26 Life Technologies Corporation Methods and systems for image analysis identification
DE112012004569T5 (de) * 2011-11-01 2014-08-14 Fresenius Kabi Oncology Ltd. Amorphe Form von Cabazitaxel und Verfahren zum Herstellen davon
CN104220431A (zh) * 2012-03-08 2014-12-17 伊瓦克斯国际有限责任公司 卡巴他赛的固态形式及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
CN104583189A (zh) * 2012-07-31 2015-04-29 永信药品工业股份有限公司 非晶型的卡巴利他索
CN102898406B (zh) * 2012-11-02 2014-12-03 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060815A (zh) * 2010-12-24 2011-05-18 重庆泰濠制药有限公司 一种紫杉烷类化合物的制备方法
WO2013034979A2 (en) * 2011-09-09 2013-03-14 Scinopharm Taiwan, Ltd. Crystalline forms of cabazitaxel
CN102503913A (zh) * 2011-10-20 2012-06-20 江苏红豆杉生物科技有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
WO2013080217A2 (en) * 2011-11-28 2013-06-06 Fresenius Kabi Oncology Ltd. Crystalline forms of carbazitaxel and process for preparation thereof
WO2013088335A1 (en) * 2011-12-13 2013-06-20 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same

Also Published As

Publication number Publication date
CN102746258B (zh) 2015-02-04
CA2909500A1 (en) 2014-01-30
US20150141674A1 (en) 2015-05-21
CN102746258A (zh) 2012-10-24
WO2014015760A1 (zh) 2014-01-30
EP3067348A1 (en) 2016-09-14
EP2835369A4 (en) 2015-12-02
CA2870569A1 (en) 2014-01-30
AU2013295924A1 (en) 2014-10-23
EP2835369B1 (en) 2019-04-03
JP2015518012A (ja) 2015-06-25
AU2016200343B2 (en) 2017-03-30
IN2014MN01962A (enExample) 2015-07-10
US9353076B2 (en) 2016-05-31
JP6329135B2 (ja) 2018-05-23
CA2909500C (en) 2018-01-09
EP2835369A1 (en) 2015-02-11
AU2016200343A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
AU2013295924B2 (en) Crystal form of cabazitaxel and preparation method thereof
CN104945375B (zh) 7‑{(3s,4s)‑3‑[(环丙基氨基)甲基]‑4‑氟吡咯烷‑1‑基}‑6‑氟‑1‑(2‑氟乙基)‑8‑甲氧基‑4‑氧‑1,4‑二氢喹啉‑3‑羧酸晶体
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
KR101917557B1 (ko) 3,5-2치환 벤젠알키닐 화합물의 결정
WO2017085628A1 (en) Process for the preparation of the amorphous form of ibrutinib and novel crystalline form
JP2019526570A (ja) アンドロゲン受容体拮抗薬の結晶形及びその製造方法並びに用途
US11639341B2 (en) Crystal form of tipifarnib and method of treatment thereof
AU2015413013A1 (en) C14-hydroxyl esterified amino acid derivatives of triptolide, and preparation method and use thereof
CN114727994B (zh) 优替德隆半水合物单晶及其制备方法与应用
WO2017025045A1 (zh) 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的新晶型及其制备方法
KR101596554B1 (ko) 펩타이드계 물질의 결정체 및 그의 제조방법과 용도
WO2012160568A1 (en) Process for preparing docetaxel trihydrate polymorph
CN108440626B (zh) 阿糖胞苷5′-o-l-缬氨酸酯盐酸盐的晶型及其制备方法
TWI680983B (zh) 一種鈉－葡萄糖共同轉運蛋白２抑制劑的ｌ－脯胺酸複合物、其一水合物及晶體
RU2712169C2 (ru) Новые полиморфные формы икотиниба фосфата и их применения
WO2022166774A1 (zh) 3-羟基-5-孕烷-20-酮衍生物的晶型及其制备方法和用途
CN111094313B (zh) 盐酸伊达比星一水合物的晶型
AU2014371150A1 (en) Crystals (2) of pyrazino[2,1-c][1,2,4]triazine compound
JP2018510173A (ja) トピロキソスタットの新規結晶形及びその製造方法
WO2015074281A1 (zh) 力格赛狄盐及其晶型、它们的制备方法和用途
CN116710102B (zh) 一种五环三萜类化合物结晶及其制备方法
WO2023202651A1 (en) Polymorphic forms of glutamine antagonist and uses thereof
CA3034535A1 (en) Novel salt of (r)-(1-methylpyrrolidine-3-yl)methyl(3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate and a crystal form thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)